# Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer

> **NCT06527690** · PHASE2 · WITHDRAWN · sponsor: **Latin American Cooperative Oncology Group**

## Conditions studied

- Prostate Cancer
- Castrate Resistant Prostate Cancer
- Homologous Recombination Deficiency

## Interventions

- **DRUG:** Niraparib/Abirate rone acetate fixed-dose combination
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT06527690
- **Lead sponsor:** Latin American Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-04-30
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-02-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study aimed to include multiple countries in Latin America, but only Brazil was feasible, making the intended ethnic and racial design unviable. Activities were closed and no sites were opened for recruitment.
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06527690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06527690, "Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06527690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*